Protocol Ledger

NCT07100938 · Phase II · TERMINATED

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Interventional Phase II clinical trial protocol NCT07100938 sponsored by BeiGene in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-21 Enrollment: 49 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07100938
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)49 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07100938
Protocol FieldVerified Registry Value
NCT IdentifierNCT07100938
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment49 participants (ACTUAL)
Registered Start Date2025-08-21
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI